ARGX
ARGENX SEPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 20 ▲ argenx announced positive Phase 3 data from the ADAPT OCULUS and ADA…
- Jun 30 ▲ 8 funds open new positions (13F)
- Aug 17 ▲ Argenx announced positive topline results from the Phase 3 ALKIVIA t…
- Aug 25 Trial readout: Results Pending: EFG PH20 SC (Phase 3), Completed 54d ago
- Aug 26 ▲ UBS upgrades
- Sep 8 Trial readout: Results Pending: EFG PH20 SC (Phase 3), Completed 68d ago
- Sep 29 ▲ argenx presented a broad set of clinical data at the 2026 AANEM and…
- Oct 8 argenx reported positive Phase 2 topline results for FB102 in celiac…
- Oct 14 to Oct 27 ▲ 3 buys: Gilbert Cisneros bought, last disclosed Nov 11
- Oct 19 ▲ argenx announced positive Phase 3 ALKIVIA results for efgartigimod i…
- Oct 22 ▲ argenx reported Q3 2026 product net sales of $1.721 billion, up 54%…
- Nov 9 ▲ argenx announced positive Phase 3 ALKIVIA data for efgartigimod in a…
Signal stack
Where each data set points today.
- InstitutionsBULLISH
Q2 2026: 46 added (8 new), 23 trimmed or exited. Largest new: Capital Research Global Investors $82.1M, Canada Pension Plan Investment Board $56.2M.
- AnalystsBULLISH
23 of 26 rate it Buy or better.
- EstimatesFALLING
Current-quarter EPS estimate $8.058 → $7.320 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +4.3% to 1.41M shares. 3.4 days to cover, ≈2.3% of shares.
- TrendUPTREND
3% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| Pictet Asset Management Holding SA | ADD | $183.8M |
| 1832 Asset Management L.P. | ADD | $146.5M |
| BARCLAYS PLC | DOUBLED | $124.7M |
| MILLENNIUM MANAGEMENT LLC | ADD | $87.6M |
| Fiera Capital Corp | TRIM | $83.9M |
| Capital Research Global Investors | NEW | $82.1M |
| Candriam S.C.A. | ADD | $74.3M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | DOUBLED | $56.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
26 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Oct 27, 2026 | Citigroup MAINTAIN | Buy |
| Oct 23, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Oct 23, 2026 | Guggenheim MAINTAIN | Buy |
| Oct 23, 2026 | Wells Fargo MAINTAIN | Overweight |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $7.32 | $6.56–$8.08 | -16.5% | $1.9B |
| Next Q | $6.49 | $6.49–$6.49 | -26.6% | $1.9B |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
19 filings · 4 press releases · 8 bullish · 0 bearish · 2 mixed · 9 neutral- BULLISH 6-KNov 9, 2026
argenx announced positive Phase 3 ALKIVIA data for efgartigimod in autoimmune myositis, meeting…
Watch for sBLA submission by end of 2026 and FDA acceptance/priority review. The DM cohort missed statistical significance, which may limit the DM label expansion path. Monitor upcoming ACR…
- NEUTRAL 6-KNov 9, 2026
argenx announced a definitive agreement to acquire Unnatural Products, Inc. (UNP) for up to $1.15…
The acquisition is a platform-expanding deal that adds peptide discovery to argenx's antibody toolkit, but the $550M upfront cash outlay will reduce cash reserves. Watch for closing conditions and…
- NEUTRAL PRESS RELEASENov 9, 2026
argenx announces acquisition of Unnatural Products (UNP) for up to $1.15 billion, adding a…
The deal adds a complementary peptide platform but is modest relative to argenx's $55.8B market cap. Watch for integration updates and any pipeline milestones that could trigger the contingent…
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 6,178,792…
Fidelity's passive stake remained at 9.9% with a modest share count increase, consistent with routine portfolio adjustments. No change in ownership level or filing type suggests no imminent activist…
All ARGX filing & press-release reports (23)
- 6-K reportNov 9, 2026
- 6-K reportNov 9, 2026
- PRESS-RELEASE reportNov 9, 2026
- SC 13G/A reportNov 5, 2026
- INST-CLUSTER reportOct 29, 2026
- 6-K reportOct 22, 2026
- 6-K reportOct 19, 2026
- 6-K reportOct 8, 2026
- 6-K reportSep 29, 2026
- INST-CLUSTER reportSep 10, 2026
- 6-K reportAug 17, 2026
- PRESS-RELEASE reportAug 6, 2026
- 6-K reportJul 27, 2026
- PRESS-RELEASE reportJul 27, 2026
- PRESS-RELEASE reportJul 23, 2026
- PRESS-RELEASE reportJul 16, 2026
- 6-K reportJun 23, 2026
- 6-K reportJun 3, 2026
- PRESS-RELEASE reportMay 8, 2026
- 6-K reportMay 6, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportApr 30, 2026
- 6-K reportApr 20, 2026